Kymera Therapeutics reported a third-quarter net loss of $132.0 million, an increase from $82.2 million in the prior-year period, driven by higher research and development expenses of $128.5 million compared to $74.1 million. The company had no collaboration revenues for the quarter, down from $2.8 million previously. Kymera also announced positive results from its KT-579 Phase 1 healthy volunteer trial, which demonstrated deep, sustained IRF5 degradation and a favorable safety profile. The firm remains well-capitalized with $1.6 billion in cash as of September 30, 2026, providing a runway into 2029. Kymera Therapeutics is a clinical-stage biotechnology company pioneering targeted protein degradation to develop oral medicines for immunological diseases.
